These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 30669895)

  • 1. Developments in the use of tyrosine kinase inhibitors in the treatment of renal cell carcinoma.
    Reed JP; Posadas EM; Figlin RA
    Expert Rev Anticancer Ther; 2019 Mar; 19(3):259-271. PubMed ID: 30669895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of tivozanib in advanced renal cell carcinoma therapy.
    Escudier B; Porta C; Eisen T; Belsey J; Gibson D; Morgan J; Motzer R
    Expert Rev Anticancer Ther; 2018 Nov; 18(11):1113-1124. PubMed ID: 30084668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is cytoreductive nephrectomy relevant in the immunotherapy era?
    Singla N; Ghandour RA; Margulis V
    Curr Opin Urol; 2019 Sep; 29(5):526-530. PubMed ID: 31305273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current State of Systemic Therapies for Advanced Renal Cell Carcinoma.
    Gulati S; Vaishampayan U
    Curr Oncol Rep; 2020 Feb; 22(3):26. PubMed ID: 32048058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical development of mTor inhibitors for renal cancer.
    Ghidini M; Petrelli F; Ghidini A; Tomasello G; Hahne JC; Passalacqua R; Barni S
    Expert Opin Investig Drugs; 2017 Nov; 26(11):1229-1237. PubMed ID: 28952411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome benefits of upfront cytoreductive nephrectomy for patients with metastatic renal cell carcinoma: An analysis of the TriNetX database.
    Lai GS; Li JR; Wang SS; Chen CS; Yang CK; Lin CY; Hung SC; Chiu KY; Yang SF
    PLoS One; 2024; 19(3):e0299102. PubMed ID: 38547226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging oral VEGF inhibitors for the treatment of renal cell carcinoma.
    Stitzlein L; Rao P; Dudley R
    Expert Opin Investig Drugs; 2019 Feb; 28(2):121-130. PubMed ID: 30572736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging tyrosine kinase inhibitors for the treatment of renal cancer.
    Iacovelli R; Albiges L; Escudier B
    Expert Opin Emerg Drugs; 2015 Sep; 20(3):379-92. PubMed ID: 25982181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor era.
    Biswas S; Kelly J; Eisen T
    Oncologist; 2009 Jan; 14(1):52-9. PubMed ID: 19147692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytoreductive Nephrectomy in the Era of Tyrosine Kinase and Immuno-Oncology Checkpoint Inhibitors.
    Biles MJ; Patel HD; Allaf ME
    Urol Clin North Am; 2020 Aug; 47(3):359-370. PubMed ID: 32600537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma.
    Ornstein MC; Rini BI
    Expert Rev Anticancer Ther; 2016 Jun; 16(6):577-84. PubMed ID: 27144724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Check point inhibitors a new era in renal cell carcinoma treatment.
    Alsharedi M; Katz H
    Med Oncol; 2018 May; 35(6):85. PubMed ID: 29728867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgery of locally advanced and metastatic kidney cancer after tyrosine kinase inhibitors therapy: single institute experience.
    De Gobbi A; Biasoni D; Catanzaro M; Nicolai N; Piva L; Stagni S; Torelli T; Procopio G; Verzoni E; Grassi P; Colecchia M; Paolini B; Spreafico C; Marchianò A; Salvioni R
    Tumori; 2018 Oct; 104(5):388-393. PubMed ID: 28085177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second-Line Therapies in the Changing Landscape of First-Line Therapies for Metastatic Clear Cell Renal Cell Cancer.
    Shaw T; Lee H; Figlin R
    Oncology (Williston Park); 2021 Jun; 35(6):306-310. PubMed ID: 34139792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein kinase inhibitors in renal cell carcinoma.
    Daste A; Grellety T; Gross-Goupil M; Ravaud A
    Expert Opin Pharmacother; 2014 Feb; 15(3):337-51. PubMed ID: 24328606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyrosine kinase and immune checkpoints inhibitors in favorable risk metastatic renal cell carcinoma: Trick or treat?
    Catalano M; Procopio G; Sepe P; Santoni M; Sessa F; Villari D; Nesi G; Roviello G
    Pharmacol Ther; 2023 Sep; 249():108499. PubMed ID: 37479037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Considerations for the Next Clinical Trial Evaluating the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma.
    Kim HL; Mayerson E; Lara PN; Messing E; Tangen C; Shuch BM; Vaishampayan U
    Eur Urol Focus; 2019 Nov; 5(6):927-929. PubMed ID: 31103605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint inhibition for the treatment of renal cell carcinoma.
    Stühler V; Maas JM; Rausch S; Stenzl A; Bedke J
    Expert Opin Biol Ther; 2020 Jan; 20(1):83-94. PubMed ID: 31587590
    [No Abstract]   [Full Text] [Related]  

  • 19. Recent developments in small molecule therapies for renal cell carcinoma.
    Song M
    Eur J Med Chem; 2017 Dec; 142():383-392. PubMed ID: 28844802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of cytoreductive nephrectomy in patients with renal cell carcinoma.
    Ghandour RA; Singla N; Margulis V
    Expert Rev Anticancer Ther; 2019 May; 19(5):405-411. PubMed ID: 31020871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.